Symbols

HROW

Harrow·NASDAQ

--(--)

HROW fundamentals

HROW Q4 2025 Earnings

Harrow (HROW) released its earnings on Mar 2, 2026: revenue was 89.09M (YoY +33.31%), missed estimates; EPS was 0.17 (YoY -29.17%), missed estimates.

Revenue / YoY

89.09M

+33.31%

EPS / YoY

0.17

-29.17%

Report date

Mar 2, 2026

HROW Earnings Call Summary for Q4,2025

Revenue Growth: 36% YoY to $272M in 2025, guided to $350-365M in 2026.
Vevye Expansion: Sales force doubling to $90M+ revenue, targeting #1 cyclosporin.
IHEEZO Momentum: 56% unit growth in 2025, Q3 2026 pricing improvement.
Pipeline Potential: G-Melt (opioid-free sedation) and Triesence cataract trial targeting $1B+ markets.
Cash Flow Strength: $44M from operations, $72.9M ending 2025.
Risks: ASC pass-through expiration, high deductible plan impact in Q1.

Earnings

EPS

Revenue

Revenue & Expenses

HROW has released its 2025 Q4 earnings report, with revenue of 89.09M, reflecting a YoY change of 33.31%, and net profit of 6.63M, showing a YoY change of -2.23%. The Sankey diagram below clearly presents HROW's revenue sources and cost distribution.

Key Indicators

Harrow (HROW) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Harrow (HROW)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Harrow (HROW)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Harrow (HROW)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown